Matritech (NASDAQ - NMPS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who wrote (561)	2/15/1998 8:33:00 PM
From: John McCarthy	Read Replies (1) of 849

Colon reminder .........FYI Info from NMPS ........... Market Size - Body Counts ------------------------------- Colorectal cancers are the second-leading cause of cancer-related deaths in the United States killing more than 55,000 people each year. The company estimates that the prevalence of colon cancer outside the United States exceeds 1.5 million people. Existing Colon test ---------------------------------- showed that Matritech's diagnostic assay for colorectal cancer was more than twice as sensitive as the only FDA-approved, blood-based colon cancer clinical assay, carcinoembryonic antigen assay (CEA) in identifying early-stage colorectal cancer (Dukes A, B1,B2). The study demonstrated CEA to be only 33 percent sensitive (8/24) in identifying patients with early-stage colorectal cancer. The Matritech test was 71 percent sensitive (17/24) in identifying early-stage colorectal cancer. WW Market Size - $ Size -------------------------- Annual worldwide sales of CEA are estimated by Matritech to exceed $100 million in sales. Per Bill's post, we're coming to bat soon. Regards, John

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next